Covetrus Inc (NASDAQ:CVET) has been given a consensus recommendation of “Hold” by the ten brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $15.20.

A number of equities research analysts have weighed in on CVET shares. Zacks Investment Research upgraded shares of Covetrus from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Thursday, November 28th. Raymond James reduced their price objective on shares of Covetrus from $45.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, August 15th. Credit Suisse Group decreased their target price on shares of Covetrus from $15.00 to $11.00 and set a “neutral” rating on the stock in a research report on Thursday, October 17th. ValuEngine cut shares of Covetrus from a “buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus lowered their target price on shares of Covetrus from $30.00 to $18.00 and set a “hold” rating on the stock in a research note on Wednesday, August 14th.

Covetrus stock traded up $0.06 during trading hours on Thursday, hitting $13.77. The stock had a trading volume of 23,747 shares, compared to its average volume of 3,185,800. The company has a 50-day moving average of $11.72 and a two-hundred day moving average of $18.05. The company has a current ratio of 1.66, a quick ratio of 0.86 and a debt-to-equity ratio of 0.86. Covetrus has a fifty-two week low of $8.16 and a fifty-two week high of $43.83.

Covetrus (NASDAQ:CVET) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.09. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $963.69 million. Covetrus had a positive return on equity of 4.26% and a negative net margin of 23.15%. The company’s revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts forecast that Covetrus will post 0.63 EPS for the current year.

A number of large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC acquired a new stake in shares of Covetrus in the 3rd quarter valued at $161,000. TimesSquare Capital Management LLC acquired a new position in Covetrus in the third quarter valued at about $3,508,000. Macquarie Group Ltd. acquired a new position in Covetrus in the second quarter valued at about $30,000. Gamco Investors INC. ET AL acquired a new position in Covetrus in the third quarter valued at about $2,338,000. Finally, First Trust Advisors LP acquired a new position in Covetrus in the third quarter valued at about $18,819,000. Hedge funds and other institutional investors own 91.27% of the company’s stock.

Covetrus Company Profile

Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.

Recommended Story: What economic reports are most valuable to investors?

Analyst Recommendations for Covetrus (NASDAQ:CVET)

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.